Michaela Wüllner

  • Citations Per Year
Learn More
1059 Background: Sorafenib is an oral RAF/RAS kinase inhibitor with antiangiogenetic potential. In metastatic BC it shows modest single agent activity but prolongs PFS in combination with capecitabine. EC-Pw or Pw-EC are standard neoadjuvant chemotherapy regimen suitable to be combined with new drugs. METHODS SOFIA is an open-label, multicentre,(More)
BACKGROUND Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, 'SOFIA'. PATIENTS AND METHODS INCLUSION CRITERIA WERE: HER2 negative, cT3, cT4 or cT2 cN+, M0 primary breast cancer. Patients received 4 × epirubicin 90 mg/m(2) and cyclophosphamide 600(More)
  • 1